Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01639482 · ClinicalTrials.gov registry record
Neuroimaging Studies of the Treatment of Bipolar Depression With Citalopram
A clinical trial of Bipolar Depression, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- 60
- Enrollment target
- 1
- Study location
NCT01639482: Completed study of Bipolar Depression, sponsored by Massachusetts General Hospital.
NCT01639482 is a study of Bipolar Depression that has completed, run by Massachusetts General Hospital. The registered enrollment target is 60 participants, below the 214-participant average among 29 other Bipolar Depression trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01639482, a study of Bipolar Depression, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
Regional metabolic changes associated with response to 6 weeks of citalopram treatment, using 18-Fluorodeoxyglucose Positron Emission Tomography imaging, will be characterized (FDG PET).
Primary Outcome
regional glucose metabolism
Conditions Studied
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - East - Charlestown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2010-04 |
| Est. Completion | 2013-12 |
What the finished NCT01639482 record still lists
NCT01639482 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 214-participant average among 29 other Bipolar Depression trials with a reported enrollment target (72% lower).
The record links to 1 condition, with Bipolar Depression appearing as the primary indexed condition, and to 0 interventions.
NCT01639482 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01639482 about?
NCT01639482 is a clinical study titled "Neuroimaging Studies of the Treatment of Bipolar Depression With Citalopram". Regional metabolic changes associated with response to 6 weeks of citalopram treatment, using 18-Fluorodeoxyglucose Positron Emission Tomography imaging, will be characterized (FDG PET).
What is the current status of trial NCT01639482?
This trial is currently completed. The enrollment target is 60 participants. The study started on 2010-04. Estimated completion is 2013-12.
What conditions does trial NCT01639482 study?
This clinical trial studies the following conditions: Bipolar Depression.
Who is sponsoring clinical trial NCT01639482?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01639482 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bipolar Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01639482's enrollment target sits among peer trials
60 17th of 29 higher than 13 of 29 other Bipolar Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Bipolar Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Xenon Inhalation Therapy for Major Depressive Disorder and Bipolar Disorder
RECRUITING · Early Phase 1
-
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
RECRUITING · Phase 3
-
University of Iowa Interventional Psychiatry Service Patient Registry
RECRUITING
-
Ketogenic Intervention for Bipolar Depression
RECRUITING · NA
-
RNA Editing as a Biomarker of Antidepressant Response in Unipolar and Bipolar Depression (EDIT-ANDRE)
RECRUITING · Phase 4
-
A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia